Research progress on the clinical application of HIV integrase inhibitors
10.3760/cma.j.cn112866-20230926-00033
- VernacularTitle:HIV整合酶抑制剂临床应用研究进展
- Author:
Yi ZHANG
1
;
Bing SONG
;
Yanze SHI
;
Minrui YU
;
Xin GUO
;
Mengmeng QU
;
Yanmei JIAO
;
Fusheng WANG
Author Information
1. 解放军总医院第五医学中心感染病医学部 国家感染性疾病临床研究中心，北京 100039
- Keywords:
Integrase inhibitor;
Human immunodeficiency virus;
Antiretroviral therapy;
Clinical efficacy;
Adverse effect
- From:
Chinese Journal of Experimental and Clinical Virology
2024;38(2):202-208
- CountryChina
- Language:Chinese
-
Abstract:
Integrase inhibitors (INSTIs) are the newest class of antiretroviral drug which are available to people living with the human immunodeficiency virus (HIV). Since 2007, five types of INSTIs have been marketed: Raltegravir, Elvitegravir, Dolutegravir, Bictegravir and Cabotegravir, all of which were approved by the US Food and Drug Administration (FDA) for use in the initiation of antiretroviral therapy (ART) in treatment-na?ve individuals. Compared with other types of antiretroviral drugs, INSTIs have better efficacy and tolerability, so many countries around the world have listed INSTIs-containing regimens as the preferred regimen for HIV ART. In recent years, with the widespread use of INSTIs, some research data suggest that INSTIs may have some adverse effects (AEs), such as central nervous system symptoms, abnormal lipid metabolism, weight gain, abnormal liver and kidney function, etc. This review summarizes the current use of INSTIs in people living with the HIV, and highlights the clinical efficacy and their AEs among the five types of INSTIs in China.
